# US 2012/0251569 A1 · Composition for treating hbv infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251569 A1
- Document ID: US20120251569A1
- Status: Published application
- Kind: A1
- Application number: 13/423,193
- Filed: 2012-03-17
- Published: 2012-10-04
- Earliest claimed: 2009-08-07
- Assignees: Transgene S.A.
- Inventors: Perrine Martin; Geneviève Inchauspe; Nathalie Silvestre; Doris Schmitt; Alexei Evlachev
- Web page: https://patentgrep.com/patent/US20120251569A1

## CPC

- A61K 39/292: {Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen}
- A61K 39/12: Viral antigens
- A61P 31/20: for DNA viruses
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2730/10134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.

## Claims

### Claim 1

An immunogenic composition comprising at least one polypeptide or a nucleic acid molecule encoding said at least one polypeptide, wherein said at least one polypeptide is selected from the group consisting of:
(i) A polymerase moiety comprising at least 450 amino acid residues of a polymerase protein originating from a first HBV virus;
(ii) A core moiety comprising at least 100 amino acid residues of a core protein originating from a second HBV virus; and
(iii) An env moiety comprising one or more immunogenic domain(s) of 15 to 100 consecutive amino acid residues of a HBsAg protein originating from a third HBV virus; or
Any combination of said polymerase moiety, core moiety, env moiety, said nucleic acid molecule encoding said polymerase moiety, said nucleic acid molecule encoding said core moiety and/or said nucleic acid molecule encoding said env moiety.

### Claim 2 (depends on 1)

The immunogenic composition according to claim 1, wherein said the immunogenic composition of the invention comprises a combination of at least two of said polymerase moiety, core moiety, env moiety or of at least two of said nucleic acid molecules encoding said polymerase moiety, said nucleic acid molecule encoding said core moiety and/or said nucleic acid molecule encoding said env moiety.

### Claim 3 (depends on 2)

The immunogenic composition according to claim 2, wherein said composition is selected from the group consisting of (i) a composition comprising a combination of said polymerase moiety and said core moiety or a combination of nucleic acid molecules encoding said polymerase moiety and said core moiety; (ii) a composition comprising a combination of said core moiety and said env moiety or a combination of nucleic acid molecules encoding said core moiety and said env moiety; and (iii) a composition comprising a combination of said polymerase moiety, said core moiety and said env moiety or a combination of nucleic acid molecules encoding said polymerase moiety, said core moiety and said env moiety.

### Claim 4 (depends on 1)

The immunogenic composition according to claim 1, wherein said first, second and third HBV virus are from different genotypes.

### Claim 5 (depends on 1)

The immunogenic composition according to claim 1, wherein at least two of said first, second and third HBV viruses are from the same HBV genotype and preferably said first, second and third HBV viruses are from the same genotype.

### Claim 6 (depends on 5)

The immunogenic composition according to claim 5, wherein said first, second and third HBV viruses are from genotype D and preferably from HBV isolate Y07587.

### Claim 7 (depends on 5)

The immunogenic composition according to claim 5, wherein said first, second and third HBV viruses are from genotype B or C

### Claim 8 (depends on 1)

The immunogenic composition according to claim 1, wherein said polymerase moiety is modified by truncation of at least 20 amino acid residues and at most 335 amino acid residues normally present at the N-terminus of a native HBV polymerase.

### Claim 9 (depends on 8)

The immunogenic composition according to claim 8, wherein said truncation includes at least 45 and at most 50 amino acid residues, and preferably the first 47 or 46 amino acid residues following the initiator Met residue located at the N-terminus of a native HBV polymerase.

### Claim 10 (depends on 9)

The immunogenic composition according to claim 9, wherein said polymerase moiety comprises an amino acid sequence which exhibits at least 80% of identity with the amino acid sequence shown in SEQ ID NO: 7.

### Claim 11 (depends on 1)

The immunogenic composition according to claim 1, wherein said polymerase moiety is modified so as to exhibit a reduced reverse-transcriptase (RTase) enzymatic activity with respect to a native HBV polymerase.

### Claim 12 (depends on 11)

The immunogenic composition according to claim 11, wherein said polymerase moiety comprises the substitution of the Asp residue corresponding to position 540 in SEQ ID NO: 1 and to position 494 in SEQ ID NO: 7 to any amino acid residue other than Asp, and preferably to a His residue.

### Claim 13 (depends on 1)

The immunogenic composition according to claim 1, wherein said polymerase moiety is modified so as to exhibit a reduced RNase H enzymatic activity with respect to a native HBV polymerase.

### Claim 14 (depends on 13)

The immunogenic composition according to claim 13, wherein said polymerase moiety comprises the substitution of the Glu residue corresponding to position 718 in SEQ ID NO: 1 and to position 672 in SEQ ID NO: 7 to any amino acid residue other than Glu, and preferably to a His residue.

### Claim 15 (depends on 14)

The immunogenic composition according to claim 14, wherein said polymerase moiety comprises an amino acid sequence which exhibits at least 80% of identity with the amino acid sequence shown in SEQ ID NO: 8 or with the amino acid sequence shown in SEQ ID NO: 7 with the substitution of the Asp residue in position 494 to an His residue and the substitution of the Glu residue in position 672 to an His residue.

### Claim 16 (depends on 1)

The immunogenic composition according to claim 1, wherein said polymerase moiety is fused in frame to a heterologous hydrophobic sequence.

### Claim 17 (depends on 16)

The immunogenic composition according to claim 16, wherein the polymerase moiety is fused in frame to the signal and trans-membrane peptides of the rabies glycoprotein and wherein said rabies signal sequence is fused in frame at the N terminus and said rabies transmembrane sequence is fused in frame at the C-terminus of said polymerase moiety.

### Claim 18 (depends on 17)

The immunogenic composition according to claim 17, wherein said polymerase moiety comprises an amino acid sequence which exhibits at least 80% of identity with the amino acid sequence shown in SEQ ID NO: 9.

### Claim 19 (depends on 1)

The immunogenic composition according to claim 1, wherein said core moiety is modified by truncation of at least 10 amino acid residues and at most 40 amino acid residues normally present at the C-terminus of a native HBV core.

### Claim 20 (depends on 19)

The immunogenic composition according to claim 19, wherein said truncation includes the last 35 amino acid residues of a native HBV core.

### Claim 21 (depends on 20)

The immunogenic composition according to claim 20, wherein said core moiety comprises an amino acid sequence which exhibits at least 80% of identity with the amino acid sequence shown in SEQ ID NO: 10.

### Claim 22 (depends on 1)

The immunogenic composition according to claim 1, wherein said core moiety is modified so as to exhibit a reduced recognition of and/or interaction with an HBV envelope protein with respect to a native HBV core.

### Claim 23 (depends on 22)

The immunogenic composition according to claim 22, wherein said core moiety comprises an amino acid sequence which exhibits at least 80% of identity with the amino acid sequence shown in SEQ ID NO: 11.

### Claim 24 (depends on 1)

The immunogenic composition according to claim 1, wherein said one or more immunogenic domain(s) in use in the present invention are selected from the group consisting of:
The portion of an env protein (HBsAg) extending from position 14-51 (env1 domain);
The portion of an env protein (HBsAg) extending from position 165-194 (env 2 domain);
The portion of an env protein (HBsAg) extending from position 81-106 (env 3 domain);
The portion of an env protein (HBsAg) extending from position 202-226 (env 4 domain); and
Any combination thereof.

### Claim 25 (depends on 24)

The immunogenic composition according to claim 24, wherein said immunogenic domain(s) comprises an amino acid sequence which exhibits at least 80% of identity with any of the amino acid sequence shown in SEQ ID NO: 12-15.

### Claim 26 (depends on 25)

The immunogenic composition according to claim 25, wherein said env moiety comprises an amino acid sequence which exhibits at least 80% of identity with the amino acid sequence shown in SEQ ID NO: 16 or in SEQ ID NO: 17.

### Claim 27 (depends on 1)

The immunogenic composition according to claim 1, wherein said polymerase, core and/or env moieties are fused in frame in a single polypeptide chain by pairs or all together.

### Claim 28 (depends on 27)

The immunogenic composition according to claim 27, wherein said env moiety is fused in frame to the C-terminus of said core moiety.

### Claim 29 (depends on 28)

The immunogenic composition according to claim 28, wherein said fusion polypeptide of the core moiety with the env moiety is selected from the group consisting of:
A polypeptide comprising an amino acid sequence which exhibits at least 80% of identity with the amino acid sequence shown in SEQ ID NO: 18;
A polypeptide comprising an amino acid sequence which exhibits at least 80% of identity with the amino acid sequence shown in SEQ ID NO: 19; and
A polypeptide comprising an amino acid sequence which exhibits at least 80% of identity with the amino acid sequence shown in SEQ ID NO: 20 or with the portion of the amino acid sequence shown in SEQ ID NO: 20 starting at residue 1 and ending at residue 251 or alternatively with the portion of the amino acid sequence shown in SEQ ID NO: 20 starting at residue 1 and ending at residue 221; or deleted versions thereof lacking residues 77-84 in SEQ ID NO: 20.

### Claim 30 (depends on 1)

A nucleic acid molecule encoding the polymerase moiety as defined in claim 1, the core moiety as defined in claim 1 and the env moiety as defined in claim 1 or any combination thereof.

### Claim 31 (depends on 30)

The nucleic acid molecule according to claim 30, wherein said nucleic acid molecule is selected from the group consisting of:
A nucleic acid molecule comprising a nucleotide sequence which exhibits at least 80% of identity with the nucleotide sequence shown in SEQ ID NO: 21;
A nucleic acid molecule comprising a nucleotide sequence which exhibits at least 80% of identity with the nucleotide sequence shown in SEQ ID NO: 22;
A nucleic acid molecule comprising a nucleotide sequence which exhibits at least 80% of identity with the nucleotide sequence shown in SEQ ID NO: 21 with the substitution of the G nucleotide in position 1480 to a C, the G nucleotide in position 2014 to a C and the A nucleotide in position 2016 to a T;
A nucleic acid molecule comprising a nucleotide sequence which exhibits at least 80% of identity with the nucleotide sequence shown in SEQ ID NO: 23;
A nucleic acid molecule comprising a nucleotide sequence which exhibits at least 80% of identity with the nucleotide sequence shown in SEQ ID NO: 24;
A nucleic acid molecule comprising a nucleotide sequence which exhibits at least 80% of identity with the nucleotide sequence shown in SEQ ID NO: 25; and
A nucleic acid molecule comprising a nucleotide sequence which exhibits at least 80% of identity with the nucleotide sequence shown in SEQ ID NO: 26 or with the portion of the nucleotide sequence shown in SEQ ID NO: 26 starting at nucleotide 1 and ending at nucleotide 753 or with the portion of the nucleotide sequence shown in SEQ ID NO: 26 starting at nucleotide 1 and ending at nucleotide 663 or deleted versions thereof lacking the portion extending from the G in position 229 to the A in position 252 of SEQ ID NO: 26.

### Claim 32 (depends on 30, 31)

A vector comprising one or more nucleic acid molecule(s) as defined in claim 30 or claim 31.

### Claim 33 (depends on 32)

The vector according to claim 32, wherein said vector is a plasmid or a viral vector.

### Claim 34 (depends on 33)

The vector according to claim 33, wherein said viral vector is a replication-defective adenoviral vector.

### Claim 35 (depends on 34)

The vector according to claim 34, wherein said nucleic acid molecule(s) is/are inserted in replacement of the E1 region.

### Claim 36 (depends on 33)

The vector according to claim 33, wherein said viral vector is a poxyiral vector and more particularly obtained from canarypox, fowlpox or vaccinia virus.

### Claim 37 (depends on 36)

The vector according to claim 36, wherein said vaccinia virus is the modified Ankara (MVA) strain.

### Claim 38 (depends on 32)

The vector according to claim 32, wherein said vector carries the nucleic acid molecules encoding said polymerase moiety, said core moiety and said env moiety.

### Claim 39 (depends on 32)

The vector according to claim 32, wherein said vector carries only one or two of the nucleic acid molecules encoding said polymerase moiety, said core moiety and said env moiety.

### Claim 40 (depends on 39)

The vector according to claim 39, wherein said vector is selected from the group consisting of:
(i) A MVA vector comprising a nucleic acid molecule placed under the control of a vaccinia promoter such as the 7.5K promoter and encoding a polymerase moiety comprising an amino acid sequence as shown in SEQ ID NO: 7, 8 or 9 or in SEQ ID NO: 7 with the substitution of the Asp residue in position 494 to an His residue and the substitution of the Glu residue in position 672 to an His residue;
(ii) A MVA vector comprising a nucleic acid molecule placed under the control of a vaccinia promoter such as the pH5r promoter and encoding a core moiety and an env moiety comprising an amino acid sequence as shown in SEQ ID NO: 18 or 19;
(iii) An E1-defective Ad vector comprising inserted in place of the E1 region a nucleic acid molecule placed under the control of the CMV promoter and encoding a polymerase moiety comprising an amino acid sequence as shown in SEQ ID NO: 7, 8 or 9 or in SEQ ID NO: 7 with the substitution of the Asp residue in position 494 to an His residue and the substitution of the Glu residue in position 672 to an His residue; and
(iv) An E1-defective Ad vector comprising inserted in place of the E1 region a nucleic acid molecule placed under the control of the CMV promoter and encoding a core moiety and an env moiety comprising an amino acid sequence as shown in SEQ ID NO: 18, 19 or 20 or the portion of SEQ ID NO: 20 starting at residue 1 and ending at residue 251 or the portion of SEQ ID NO: 20 starting at residue 1 and ending at residue 221.

### Claim 41 (depends on 30, 31, 32)

An infectious viral particle comprising the nucleic acid molecule according to claim 30 or claim 31 or the vector according to claim 32.

### Claim 42 (depends on 41)

The infectious viral particle according to claim 41, wherein said infectious viral particles is produced by a process comprising the steps of:
(e) introducing the viral vector of the invention into a suitable cell line,
(f) culturing said cell line under suitable conditions so as to allow the production of said infectious viral particle,
(g) recovering the produced infectious viral particle from the culture of said cell line, and
(h) optionally purifying said recovered infectious viral particle.

### Claim 43 (depends on 30, 31, 32, 42, 43)

A host cell comprising the nucleic acid molecule according to claim 30 or claim 31, the vector according to claim 32 or the infectious viral particle according to claim 42 or claim 43.

### Claim 44 (depends on 30, 31, 32, 42, 43)

A composition comprising the nucleic acid molecule according to claim 30 or claim 31, the vector according to claim 32, or the infectious viral particle according to claim 42 or the host cell according to claim 42, or the host cell according to claim 43 and a pharmaceutically acceptable vehicle.

### Claim 45 (depends on 44)

The composition according to claim 44 which further comprises one or more adjuvant(s) suitable for systemic or mucosal application in humans.

### Claim 46 (depends on 44, 45)

The composition according to claim 44 or claim 45 which is formulated for intramuscular or subcutaneous administration.

### Claim 47 (depends on 44)

The composition according to claim 44, which comprises from about 105 to about 1013 infection units of a viral vector or of an infectious viral particle.

### Claim 48 (depends on 1, 30, 31, 32, 41, 42, 43, 44)

Use of at least one of the HBV moieties as defined in claim 1, of the immunogenic composition according to claim 1, of the nucleic acid molecule according to claim 30 or claim 31, of the vector according to claim 32, of the infectious viral particle according to claim 41 or claim 42, of the host cell according to claim 43, or of the composition according to claim 44 for the preparation of a drug intended for treating or preventing an HBV infection or an HBV-associated disease or pathologic condition.

### Claim 49 (depends on 1, 30, 31, 32, 41, 43, 44)

A method for the treatment or prevention of an HBV infection, or an HBV-associated disease or pathologic condition, comprising administering to a human or animal organism in need thereof a therapeutically effective amount of at least one of the HBV moieties as defined in claim 1, of the immunogenic composition according to claim 1, of the nucleic acid molecule according to claim 30 or claim 31, of the vector according to claim 32, of the infectious viral particle according to claim 41, of the host cell according to claim 43, or of the composition according to anyone of claim 44.

### Claim 50 (depends on 48, 49)

The use according to claim 48 or the method according to claim 49, for treating a patient having a chronic hepatitis B viral infection.

### Claim 51 (depends on 48)

The method or use according to claim 48, wherein said method or use is used in combination with standard of care.

### Claim 52 (depends on 51)

The method or use according to claim 51, wherein said standard of care comprises cytokines and/or nucleotide or nucleoside analogs selected from the group consisting of lamivudine, entecavir, telbivudine, adefovir, dipivoxil and tenofovir.

### Claim 53 (depends on 1, 30, 31, 32, 41, 43, 44)

A method of inducing or stimulating an immune response against HBV in a host organism comprising administering to said organism at least one of the HBV moieties as defined in claim 1, of the immunogenic composition according to claim 1, of the nucleic acid molecule according to claim 30 or claim 31, of the vector according to claim 32, of the infectious viral particle according to claim 41, of the host cell according to claim 43, or of the composition according to claim 44, so as to induce or stimulate said immune response.

### Claim 54 (depends on 53)

The method of claim 53, wherein said immune response is cellular and CD4+and/or CD8+-mediated.

### Claim 55 (depends on 1, 30, 31, 32, 41, 43, 44)

A kit of parts for use in the treatment of an HBV infection, wherein said kit comprises a plurality of active agents selected from the group consisting of the HBV moieties as defined in claim 1, of the immunogenic composition according to claim 1, of the nucleic acid molecule according to claim 30 or claim 31, of the vector according to claim 32, of the infectious viral particle according to claim 41, of the host cell according to claim 43, or of the composition according to claim 44.

### Claim 56 (depends on 1, 55)

The kit of parts of claim 55, which comprises a first vector comprising a nucleic acid molecule encoding the polymerase moiety as defined in claim 1 and a second vector comprising a nucleic acid molecule encoding the core moiety and/or the env moiety as defined in claim 1.

### Claim 57 (depends on 40, 56)

The kit of part according to claim 56, wherein said first vector is a MVA vector as defined in claim 40(i) and said second vector is a MVA vector as defined in claim 40(ii).

### Claim 58 (depends on 40, 56)

The kit of part according to claim 56, wherein said first vector is an Ad vector as defined in claim 40(iii) and said second vector is an Ad vector as defined in claim 40(iv).

### Claim 59 (depends on 56)

The kit of part according to claim 56, further comprising a third vector expressing an immunomodulator.

### Claim 60 (depends on 1, 30, 31, 32, 41, 43, 44)

The immunogenic composition according to claim 1, the nucleic acid molecule according to claim 30 or claim 31, the vector according to claim 32, the infectious viral particle according to claim 41, the host cell according to claim 43 or the composition according to claim 44 for use in a subject infected with or suspected to be infected with an HBV for the treatment of an HBV infection, and especially a chronic HBV infection, wherein said subject is infected or suspected to be infected with an HBV from a genotype that is different from the HBV genotype administered to said subject.

### Claim 61 (depends on 1, 30, 31, 32, 41, 43, 44)

A method of treating an HBV infection, and especially a chronic HBV infection in a subject in need thereof comprising the step of a) identifying a subject infected or suspected to be infected with an HBV; b) administering to the subject a sufficient amount of the immunogenic composition according to claim 1, the nucleic acid molecule according to claim 30 or claim 31, the vector according to claim 32, the infectious viral particle according to claim 41, the host cell according to claim 43 or the composition according to claim 44; wherein said subject is infected or suspected to be infected with an HBV from a genotype that is different from the HBV genotype administered to said subject.

### Claim 62 (depends on 1, 30, 31, 32, 41, 43, 44)

A method of treating a disease or condition associated with an HBV infection, and especially a chronic HBV infection in a subject in need thereof comprising the step of a) identifying a subject infected or suspected to be infected with an HBV; b) administering to the subject a sufficient amount of the immunogenic composition according to claim 1, the nucleic acid molecule according to claim 30 or claim 31, the vector according to claim 32, the infectious viral particle according to claim 41, the host cell according to claim 43 or the composition according to claim 44; wherein said subject is infected or suspected to be infected with an HBV from a genotype that is different from the HBV genotype administered to said subject.

### Claim 63 (depends on 60, 61)

The immunogenic composition, the nucleic acid molecule, the vector, the infectious viral particle, the host cell or the composition for use according to claim 60 or the method of treating according to claim 61, wherein said subject is infected or suspected to be infected with an HBV from a genotype B or C and wherein the HBV genotype administered to said subject is of genotype D.

### Claim 64 (depends on 6, 63)

The immunogenic composition, the nucleic acid molecule, the vector, the infectious viral particle, the host cell or the composition for use according to claim 63 or the method of treating according to claim 63, wherein said immunogenic composition is as defined in claim 6.

### Claim 65 (depends on 18, 23, 26, 29, 64)

The immunogenic composition, the nucleic acid molecule, the vector, the infectious viral particle, the host cell or the composition for use according to claim 64 or the method of treating according to claim 64, wherein said polymerase moiety comprised in said immunogenic composition is as defined in claim 18, said core moiety comprised in said immunogenic composition is as defined in claim 23 and/or said env moiety comprised in said immunogenic composition is as defined in claim 26 or claim 29.

### Claim 66 (depends on 60, 61)

The immunogenic composition, the nucleic acid molecule, the vector, the infectious viral particle, the host cell or the composition for use according to claim 60 or the method of treating according to claim 61, wherein said method or use is used in combination with standard of care.
